Figure 3 The 'leaky gut' hypothesis

Slides:

Advertisements

Similar presentations

What’s All the Fuss About the Microbiome?

Advertisements

Volume 141, Issue 5, Pages (November 2011)

Volume 141, Issue 5, Pages (November 2011)

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Low-grade inflammation in FGID

Figure 4 The gut microbiota directly influences T-cell differentiation

Figure 3 Neutrophils in liver inflammation

Figure 4 Interactions between adipose, the microbiome and kidney

Figure 1 Differential immune responses in the gut (oral tolerance)

Figure 1 Contribution of the gut microbiota

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 The fat–intestine–kidney axis

Figure 1 Gut microorganisms at the intersection of several diseases

Figure 5 Lipid droplet consumption

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 The microbiome–gut–brain axis

Volume 141, Issue 5, Pages (November 2011)

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Endocrinol. doi: /nrendo

The gut microbiota and the liver

Figure 4 Tumour-induced neutrophil extracellular trap

Figure 1 Schematic outlining the results of Buffington et al.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Polysaccharides from plants and mushrooms

Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.

Figure 1 Definition and concept of ACLF

Figure 1 Functions, features and phenotypes of HSCs in normal and diseased livers Figure 1 | Functions, features and phenotypes of HSCs in normal and diseased.

Figure 4 The gut–kidney axis, inflammation and cardiovascular disease in CKD Figure 4 | The gut–kidney axis, inflammation and cardiovascular disease in.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

David L. McCollum, J. Martin Rodriguez

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 5 Intestinal lymph draining pattern and contents

Figure 1 An overview of the TIMER microbiota–host

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

to the liver and promote patient-derived xenograft tumour growth

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 13C-octanoic acid gastric emptying breath test

Figure 5 Chrononutrition in the liver

Figure 2 Key brain–immune–gut interactions

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Three distinct paracellular epithelial

Figure 1 Key mechanistic pathways involved in the gut–liver axis in NAFLD progression Figure 1 | Key mechanistic pathways involved in the gut–liver axis.

Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Influence of diet on gut microbiota and blood pressure

Figure 1 Animal models of liver regeneration

Figure 4 The gut–liver relationship in PSC

Figure 2 Pro-inflammatory and anti-inflammatory effects of the gut microbiota Figure 2 | Pro-inflammatory and anti-inflammatory effects of the gut microbiota.

Figure 3 Strategies to improve liver regeneration

The National Biome Initiative: An allergy perspective

Figure 1 Brain–gut axis Brain–gut axis. Schematic of the brain–gut axis, including inputs from the gut microbiota, the ENS, the immune system and the external.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 New therapeutic approaches in IBD with their specific targets

Figure 5 Systems biological model of IBS

Figure 2 The hypoxia-induced proinflammatory

Figure 4 Local species pools that contribute to the

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Hans-Joachim Anders, Kirstin Andersen, Bärbel Stecher

Figure 1 New therapeutic approaches in IBD therapy based on blockade of T-cell homing and retention Figure 1 | New therapeutic approaches in IBD therapy.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Lifelong influences on the gut microbiome from

The Gastrointestinal Tumor Microenvironment

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Inflammatory pathways in alcoholic steatohepatitis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Presentation transcript:

Figure 3 The 'leaky gut' hypothesis Figure 3 | The 'leaky gut' hypothesis. a | The normal intestine — an intact barrier, including tight junctions — prevents translocation of bacteria and/or bacterial components or products into the submucosal compartment. b | The 'leaky gut': disruption of tight junction integrity permits bacteria (from a normal or altered gut microbiota) to access the submucosa, where they activate mast cells and lymphocytes that release products such as mast cell proteases and cytokines and chemokines, which lead to inflammation and activation of sensory neurons. Access is also provided to the vasculature and thereby to the portal circulation, the liver and potentially the systemic circulation. As discussed in the main text, this hypothesis is an oversimplification of interactions between the microbiota and the gut barrier, and many of the aforementioned steps have not been demonstrated in humans. Quigley, E. M. M. (2017) Gut microbiome as a clinical tool in gastrointestinal disease management: are we there yet? Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2017.29